SequelSEC

HAEMONETICS CORP HAE

Surgical & Medical Instruments & Apparatus · CIK 0000313143 · Fiscal year ends 0403

AnnualQuarterlyTTM
Revenue
$339.38M
Fiscal year ended 2026-06-27
Operating income
$57.46M
Fiscal year ended 2026-06-27
Free cash flow
$44.42M
Fiscal year ended 2026-06-27

HAEMONETICS CORP (HAE) reported revenue of $339.38M and net income of $33.01M for the fiscal year ended 2026-06-27. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from HAEMONETICS CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

HAEMONETICS CORP income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-272026-03-282025-12-272025-09-272025-06-282025-03-292024-12-282024-09-282024-06-292024-03-30
Revenue$339.38M$346.35M$338.97M$327.32M$321.39M$330.60M$348.54M$345.51M$336.17M$343.29M
Cost of revenue$136.58M$148.14M$136.58M$132.57M$129.15M$137.55M$155.00M$158.07M$161.25M$167.38M
Gross profit$202.80M$198.21M$202.39M$194.74M$192.24M$193.05M$193.55M$187.44M$174.92M$175.91M
Operating income$57.46M-$23.02M$67.40M$58.49M$53.87M$71.34M$59.03M$51.70M$39.76M$29.94M
Net income$33.01M-$20.15M$44.74M$38.68M$34.03M$57.98M$37.49M$33.83M$38.37M$20.37M
Research & development$16.20M$14.45M$14.19M$14.87M$16.26M$18.30M$15.83M$14.14M$14.45M$15.86M
Weighted-average diluted sharesshares 45.70MUnavailableshares 46.99Mshares 47.66Mshares 48.35MUnavailableshares 50.64Mshares 51.24Mshares 51.56MUnavailable
Pretax income$47.57M-$28.40M$59.98M$51.28M$45.17M$70.74M$49.92M$44.70M$46.71M$23.41M
Income tax expense$14.56M-$8.25M$15.24M$12.60M$11.14M$12.76M$12.42M$10.87M$8.34M$3.05M
Diluted EPS$0.72Unavailable$0.95$0.81$0.70Unavailable$0.74$0.66$0.74Unavailable
Selling, general & administrative$118.94M$120.93M$109.15M$101.62M$110.72M$115.14M$106.46M$106.95M$108.25M$109.26M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

HAEMONETICS CORP balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-272026-03-282025-12-272025-09-272025-06-282025-03-292024-12-282024-09-282024-06-292024-03-30
Cash & equivalents$223.38M$245.44M$363.37M$296.43M$292.90M$306.76M$320.85M$299.28M$344.43M$178.80M
Total assets$2.37B$2.40B$2.49B$2.44B$2.46B$2.45B$2.53B$2.53B$2.54B$2.20B
Current assets$810.83M$834.88M$943.67M$899.68M$913.16M$934.98M$1.01B$955.90M$978.58M$768.90M
Total liabilitiesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current liabilities$263.24M$282.60M$539.87M$548.32M$531.41M$578.11M$253.23M$273.95M$260.08M$300.38M
Total equity incl. NCI$837.10M$796.32M$911.45M$849.17M$882.30M$820.84M$906.86M$878.85M$905.37M$959.96M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$306.74M$306.37M$321.18M$336.21M$360.53M$365.14M$359.61M$382.10M$373.79M$317.20M
Accounts receivable$216.07M$216.86M$195.71M$207.07M$200.75M$202.66M$211.95M$213.53M$201.48M$206.56M
Goodwill$656.88M$656.37M$606.82M$606.10M$607.30M$604.27M$605.27M$616.16M$613.35M$565.08M
Long-term debt$1.17B$1.22B$919.99M$920.39M$920.83M$921.23M$1.22B$1.22B$1.22B$797.56M
Accounts payable$56.34M$51.06M$48.69M$61.69M$46.01M$67.00M$62.99M$69.24M$76.93M$73.36M

Cash flow

HAEMONETICS CORP cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-272026-03-282025-12-272025-09-272025-06-282025-03-292024-12-282024-09-282024-06-292024-03-30
Operating cash flow$52.32M$70.94M$93.56M$111.32M$17.40M$116.56M$43.77M$48.82M-$27.42M$64.08M
Capital expenditures$7.91M$17.66M$6.35M$5.02M$3.75M$15.64M$8.55M$9.43M$5.66M$6.68M
Investing cash flow-$22.23M-$86.61M-$29.47M-$30.47M-$33.00M$18.04M-$17.37M-$23.37M-$139.20M-$13.06M
Financing cash flow-$51.53M-$101.50M$2.03M-$76.55M-$2.44M-$151.45M$1.38M-$74.80M$333.69M-$63.50M
Net change in cash-$22.06M-$117.93M$66.94M$3.53M-$13.86M-$14.08M$21.56M-$45.15M$165.63M-$15.18M
Stock-based compensation$9.31M$9.13M$7.80M$7.59M$9.31M$6.94M$8.21M$6.86M$7.63M$7.42M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailable$100.00M$0UnavailableUnavailable$150.00M$0UnavailableUnavailable$0
Depreciation & amortization$27.11M$27.32M$27.38M$28.26M$28.76M$28.21M$29.02M$29.22M$29.14M$27.64M

Derived

HAEMONETICS CORP derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-272026-03-282025-12-272025-09-272025-06-282025-03-292024-12-282024-09-282024-06-292024-03-30
Free cash flow$44.42M$53.28M$87.22M$106.30M$13.64M$100.91M$35.22M$39.39M-$33.08M$57.40M
Gross margin59.8%57.2%59.7%59.5%59.8%58.4%55.5%54.2%52.0%51.2%
Operating margin16.9%-6.6%19.9%17.9%16.8%21.6%16.9%15.0%11.8%8.7%
FCF margin13.1%15.4%25.7%32.5%4.2%30.5%10.1%11.4%-9.8%16.7%
SBC / revenue2.7%2.6%2.3%2.3%2.9%2.1%2.4%2.0%2.3%2.2%
Current ratio3.08x2.95x1.75x1.64x1.72x1.62x3.97x3.49x3.76x2.56x
Revenue YoY growth5.6%4.8%-2.7%-5.3%-4.4%-3.7%3.7%8.6%8.0%12.8%
Net margin9.7%-5.8%13.2%Unavailable10.6%17.5%10.8%UnavailableUnavailable5.9%
R&D / revenue4.8%4.2%4.2%4.5%5.1%5.5%4.5%4.1%4.3%4.6%
CapEx / revenue2.3%5.1%1.9%1.5%1.2%4.7%2.5%2.7%1.7%1.9%
Long-term debt / equity1.40x1.53x1.01xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate30.6%Unavailable25.4%24.6%24.7%18.0%24.9%24.3%17.9%13.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HAE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-K · Filed 2026-05-20View SEC filing
10-Q · Filed 2026-02-05View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-K · Filed 2025-05-21View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.